TL;DR
This study investigated whether premixing lidocaine with fospropofol, a propofol prodrug, could reduce the common side effect of paresthesia (tingling, itching sensations) during anesthesia induction. While preclinical studies showed promising synergistic effects on sedation and analgesia, the randomized controlled trial found that lidocaine did not significantly alleviate fospropofol-induced paresthesia in human patients.
What Problem Does This Paper Address?
Fospropofol is a water-soluble prodrug of propofol, designed to overcome some of propofol's limitations, such as injection pain. However, a significant drawback of fospropofol is its tendency to cause paresthesia, an unpleasant sensory side effect that can occur during anesthesia induction. While intravenous lidocaine has been shown to mitigate paresthesia induced by other drugs like dexamethasone, its efficacy in preventing fospropofol-induced paresthesia was unknown. This paper aims to fill that knowledge gap by evaluating the safety and effectiveness of combining lidocaine with fospropofol.
Methods
The research employed a two-pronged approach:
- Preclinical Experimental Study:
- In vitro: Physicochemical compatibility of fospropofol and lidocaine mixtures was assessed for stability and pH over 14 days. High-performance liquid chromatography (HPLC) was used to determine drug concentrations over time.
- In vivo (Rat Model): Safety was evaluated by measuring liver and kidney function markers (ALT, AST, creatinine, urea) and examining tissue histology. Pharmacodynamic effects were assessed by measuring sedation onset and duration, and analgesic effects by observing the pinch reflex. Hemodynamic and respiratory parameters were also monitored.
- Randomized Controlled Trial (RCT):
- Adult surgical patients were randomized into two groups: one receiving fospropofol premixed with lidocaine (FP+LD) and the other receiving fospropofol with normal saline (FP+NS).
- The primary outcome was the incidence of paresthesia. Secondary outcomes included other paresthesia-related symptoms, injection pain, sedation efficacy, hemodynamic stability, and plasma inflammatory markers.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- Preclinical Promise, Clinical Reality: The preclinical studies in rats suggested that combining lidocaine with fospropofol could enhance sedative and analgesic effects, leading to faster sedation onset and longer duration without significant adverse events. This created an expectation that it might also reduce paresthesia.
- Paresthesia Mechanism Remains Elusive: Despite lidocaine's known effects on sodium channels and its success with other drugs, it failed to significantly reduce the incidence of paresthesia caused by fospropofol. This suggests that the underlying mechanisms of paresthesia induced by fospropofol may differ from those induced by dexamethasone.
- Phosphate's Potential Role: The study observed an increase in plasma phosphate levels post-administration in both groups, and the authors hypothesize that this, rather than direct nerve irritation, might play a critical role in fospropofol-induced paresthesia. This aligns with previous research linking phosphate metabolism to pruritus.
- Timing is Key: Paresthesia induced by fospropofol consistently occurred within a narrow window of 40-60 seconds after administration, highlighting the critical period of transition from consciousness to sedation.
- Limited Impact on Whole-Body Paresthesia: While not statistically significant, the FP+LD group showed a lower absolute proportion of whole-body paresthesia compared to the FP+NS group, hinting at a potential, albeit minor, effect that warrants further investigation in larger studies.
Key Results
- Preclinical:
- Fospropofol and lidocaine mixtures were physicochemically stable.
- The premixed solution showed faster sedation onset and longer sedation duration in rats compared to fospropofol alone.
- The 7.5 LFP group demonstrated a significantly higher incidence of pinch reflex disappearance (analgesic effect).
- No significant differences in liver/kidney function or major hemodynamic/respiratory adverse events were observed in rats.
- Clinical:
- The incidence of paresthesia was high and similar in both groups: 83.3% in the FP+LD group and 83.3% in the FP+NS group (p > 0.990).
- Lidocaine did not significantly affect the onset time or duration of paresthesia.
- Tingling was the most common type of paresthesia, predominantly affecting the perineal region in both groups.
- Plasma phosphate levels increased in both groups after administration.
- No significant differences were found in plasma inflammatory markers (IL-6, His, TNF-a) between the groups.
- The FP+LD group showed slightly higher blood pressure at 1 minute post-administration, but overall hemodynamic stability was comparable.
Limitations and Future Work
- Limitations:
- The preclinical study could not reliably assess pruritus-related outcomes in rats due to rapid loss of consciousness.
- The clinical study was single-center, which may limit generalizability.
- The subjective nature of paresthesia assessment and frequent questioning could introduce bias.
- Limited detection of all potential biochemical markers related to paresthesia.
- Future Work:
- Further research is needed to explore more effective methods for anesthesia induction that facilitate a rapid transition to a sedative state.
- Larger sample size studies are warranted to confirm the potential synergistic interaction of lidocaine and fospropofol on sedation and to investigate the observed trend of reduced whole-body paresthesia with lidocaine.
- Investigating the role of plasma phosphate in fospropofol-induced paresthesia requires further exploration.
- Understanding the differing mechanisms of paresthesia induced by fospropofol versus other drugs like dexamethasone is crucial.
Summary updated